SecBot SecBot

HKMPF

HKMPF
$22.14 +0.00 (+0.00%)
Oct 27 4:00 PM ET · prev $22.14
1 year
−6.0%
from $23.55 · Oct 28
30 days
+4.9%
from $21.10
52-week range
$16.34–24.32
−9% from high · low Mar 6
Avg volume 20D
195
Oct 8 spike 3.8K
Short interest
154.5K
+5.7%
Days to cover
130.4
at average volume
Filing reports
3
analyzed by SecBot
SecBot read MIXED 2 reports · latest
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/2
Strongest NEUTRAL Hikma Pharmaceuticals USA, Inc. is a plaintiff in a trade-secret-related lawsuit against InfoRLife SA and WG…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • Short sellersSTEADY

    Short interest +5.7% to 154.5K shares. 130.4 days to cover.

  • TrendUPTREND

    2% above its 50-day average.

Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 27, 2026
Clinical Trial
🔒 Fresh data, subscribers only
Oct 23, 2026
Clinical Trial
Comparison of Corticosteroids vs Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the ICU
Phase 3 · COMPLETED
Oct 21, 2026
Clinical Trial
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer
Phase 2 · COMPLETED
Oct 8, 2026
Clinical Trial
A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.
Phase 3 · COMPLETED
Oct 6, 2026
Clinical Trial
Sex Differences in Neurobehavioral Response to THC
Phase 2 · TERMINATED

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
154,509
shares short
+5.7%
vs prior settlement
130.4
days to cover
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 18, 2026 Event
INFUMORPH 200
Unavailable: Additional lots will be available in the October 2026 timeframe. Product will be made a
Jun 26, 2026 Drug approval
EMA: Human medicines European public assessment report (EPAR): Denosumab Ascend, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Denosumab Ascend, denosumab, Status: Opini
Jun 4, 2026 SEC
The Supreme Court unanimously reversed the Federal Circuit and dismissed Amarin's induced-infringement suit against…
COURT-RULING — Impact 7/10
Jun 4, 2026 Event
Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
Court ruling from Supreme Court of the United States. Docket: 24-889
Apr 20, 2026 SEC
Hikma Pharmaceuticals USA, Inc. is a plaintiff in a trade-secret-related lawsuit against InfoRLife SA and WG Critical…
COURT-RULING — Impact 1/10
Apr 20, 2026 SEC
The court granted a motion to seal confidential information from a December 2025 teleconference transcript in the…
COURT-RULING — Impact 1/10

SecBot reports

3 filings · 1 bullish · 0 bearish · 2 neutral
All HKMPF filing & press-release reports (3)